Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Next Previous
Trial Profile

A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romosozumab (Primary) ; Bisphosphonates
  • Indications Osteogenesis imperfecta
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 18 Nov 2024 The protocol has been amended to change in time frame for Primary Outcome Measures Change from Baseline to 12 Months in Lumbar Spine BMD Z-score.
  • 30 Apr 2024 Planned End Date changed from 10 Sep 2027 to 6 Sep 2027.
  • 30 Apr 2024 Planned primary completion date changed from 7 Jun 2027 to 3 Jun 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top